Key result
Anthracycline-based chemotherapy was associated with a 5% decline in both LVEF (P<0.0001) and LV mass (P=0.03) at 6 months, with LV mass reductions correlating with worsening heart failure symptoms.
Why the study?
Does anthracycline-based chemotherapy reduce left ventricular mass and worsen heart failure symptomatology in cancer patients?
Population
100 participants including cancer patients and healthy controls, mean age 51±12 years, 70% women. Cancer…
Comparison
Anthracycline-based chemotherapy (Anth-bC) vs Non-anthracycline-based chemotherapy and…
Design
Cohort, blinded assessments
Follow-up
6 months
Authors
Loading...
LV mass decline after anthracyclines may signal early cardiotoxicity; hypothesis-generating for mass monitoring beyond LVEF in cardio-oncology.
Cohort (n=100)
Blinded assessments
Does anthracycline-based chemotherapy reduce left ventricular mass and worsen heart failure symptomatology in cancer patients?
p-value: p=<0.0001 for LVEF, 0.03 for LV mass
Anthracycline-based chemotherapy induces early left ventricular mass reductions that correlate with worsening heart failure symptoms independently of LVEF changes, suggesting LV mass should be monitored during cardio-oncology surveillance.
Jordan et al. (2018) conducted a cohort in Cancer (breast, hematologic, soft tissue sarcoma) (n=100). Anthracycline-based chemotherapy vs. Non-anthracycline-based chemotherapy and cancer-free controls was evaluated on Decline in LVEF and LV mass (p=<0.0001 for LVEF, 0.03 for LV mass). Anthracycline-based chemotherapy was associated with a 5% decline in both LVEF (P<0.0001) and LV mass (P=0.03) at 6 months, with LV mass reductions correlating with worsening heart failure symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: